Veraxa Biotech AG VRXA
0.99 USD -0.04 (-3.88%)
At closeNov 3, 2026, 4:00 PM EST
1.10 +0.11 +11.11%
After hours · Nov 3, 4:00 PM ET
0.9623 Day range 1.06
0.95 52-week range 27.36
- YTD
- -90.72%
- 1 year
- -90.56%
News
globenewswire.com VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.
barrons.com Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.'
globenewswire.com VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
globenewswire.com VERAXA Biotech Appoints Raju Willener as Chief Financial Officer Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today…
benzinga.com VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a company
globenewswire.com VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent…
benzinga.com VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
globenewswire.com VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of…
globenewswire.com VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an…
globenewswire.com VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph…
benzinga.com VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA))), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the
globenewswire.com VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from…
benzinga.com VERAXA Biotech Partners With AI-Driven Computational R&D Partner Ardigen To Support Its Growing BiTAC Pipeline Of T Cell Engagers And Antibody Drug Conjugates The collaboration is another milestone in VEREXA’s mission to integrate AI into its research and development, with the long-term goal to achieve success rates in drug development that exceed industry…
globenewswire.com VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline ZURICH, SWITZERLAND - July 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S. A. , an…
benzinga.com FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.- benzinga.com VERAXA Biotech Appoints Carl Von Halem As Interim CFO, Succeeding Torsten Bürgermeister VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds…
globenewswire.com VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister ZURICH, SWITZERLAND - July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim…
benzinga.com Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…- benzinga.com VERAXA Biotech Channels Investment Into BiTAC Portfolio, Eyes BiTAC-TCE Candidate VXA-102 IND/CTA-Ready By 2028 VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update."In the first six months of 2026, we have made…
globenewswire.com VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals…- benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
- benzinga.com Veraxa Biotech Initiated Cell Line Development For Its Lead BiTAC T-cell Engager Program VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC® T-cell engager…
globenewswire.com VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program ZURICH, SWITZERLAND - July 02, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
benzinga.com VERAXA Biotech Moves Into Additional Laboratory Space At Existing R&D Site In Heidelberg, Germany, To Support Team Growth And Infrastructure Build‑Out VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D…
globenewswire.com VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
globenewswire.com VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026 ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro…
benzinga.com Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
benzinga.com Why La-Z-Boy Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expected results and announcing a $300 million share buyback.
benzinga.com Crude Oil Down Over 3%; US Consumer Sentiment Rises In June Dow Jones up 0.56%, NASDAQ up 0.08%, S&P 500 up 0.32%. Materials shares rise 1.7%, consumer discretionary down 1.3%. University of Michigan's consumer sentiment index beats estimates. Oil down 3.3%,…
benzinga.com VERAXA Biotech And Voyager Acquisition Complete Business Combination; On June 11, 2026, VERAXA Will Commence Trading Its Shares Under The Symbol "VRXA" Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel…